Showing 7001-7010 of 8649 results for "".
- Opus Genetics Phase 3 Trial for Phentolamine Ophthalmic Solution Meets Primary Endpoint for Night Visionhttps://modernod.com/news/opus-genetics-phase-3-trial-for-phentolamine-ophthalmic-solution-meets-primary-endpoint-for-night-vision/2482828/Opus Genetics announced positive topline results from LYNX-2, a phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Patients who undergo kera
- University of Oklahoma Study Identifies 20 Novel Variants for Inherited Retinal Diseaseshttps://modernod.com/news/university-of-oklahoma-study-identifies-20-novel-variants-for-inherited-retinal-diseases/2482824/A new study out of the University of Oklahoma maps 20 new gene mutations contributing to rare inherited retinal diseases (IRDs). Researchers aim to use these findings to improve diagnostic accuracy and identify targets for future
- Nicox to Receive Milestone Payments from Kowa as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japanhttps://modernod.com/news/nicox-to-receive-milestone-payments-from-kowa-as-ncx-470-prepares-to-enter-phase-3-clinical-trials-in-japan/2482819/Nicox SA announced that its exclusive Japanese partner for NCX 470, Kowa, has received Clinical Trial Notification (equivalent of a US Investigational New Drug, IND) approval to initiate phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Ja
- Grifols Receives FDA Clearance to Initiate Phase 2 Trial of Immunoglobulin Drops for Dry Eye Diseasehttps://modernod.com/news/grifols-receives-fda-clearance-of-ind-application-for-phase-2-trial-of-immunoglobulin-drops-for-dry-eye-disease/2482812/Grifols, a producer of plasma-derived medicines, announced that the FDA has cleared the company’s investigational new drug (IND) application to initiate a phase 2 trial evaluating its immunoglobulin (IG) drops–GRF312 ophthalmic solution–fo
- Nationwide Recall Issued for Multiple OTC Eye Care Productshttps://modernod.com/news/nationwide-recall-issued-for-multiple-otc-eye-care-products/2482809/A voluntary recall for multiple OTC eye care products, including artificial tears and lubricant eye drops, was issued due to serious manufacturing violations identified during an FDA audit. The
- EYE-GO Secures Strategic Investment from Topcon Healthcarehttps://modernod.com/news/eye-go-secures-strategic-investment-from-topcon-healthcare/2482807/EYE-GO, a Danish MedTech company, today announced that Topcon Healthcare, Inc will become a strategic investor in their company. According to EYE-GO, the collaboration reflects a shared vision to revolutionize chronic eye disease management through evidence-
- Intalight Receives CE Mark for its DREAM OCT Platformhttps://modernod.com/news/intalight-receives-ce-mark-for-its-dream-oct-platform-approal-for-commercialization-in-europe/2482804/Intalight announced it has received CE mark for its
- Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Resultshttps://modernod.com/news/isarna-therapeutics-presents-positive-phase-2-better-trial-final-results-at-arvo-2025/2482797/Isarna Therapeutics presented final positive results from its phase 2 BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on May 6. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, shared data
- Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine Reduced Lesion Growth in Phase 2 Study in GAhttps://modernod.com/news/cognition-therapeutics-reports-topline-results-showing-oral-zervimesine-reduced-lesion-growth-in-phase-2-study-in-ga/2482793/Cognition Therapeutics reported topline results from the Phase 2 COG2201 ‘MAGNIFY’ trial of zervimesine (CT1812) in adults with geographic atrophy (GA). The results show zervimesine-treated participants had 28.6% slower GA lesion growth on average and at 18 months, and their lesi
- Kiora Pharmaceuticals Presents In Data Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathyhttps://modernod.com/news/kiora-pharmaceuticals-presents-in-data-demonstrating-the-potential-of-kio-104-to-treat-proliferative-vitreoretinopathy/2482784/Kiora Pharmaceuticals announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The presentation, titled, "KIO-104, a novel small molecule inhibitor o